Bioidentical hormones vs standard HRT: what is the difference?

Short answer

• “Bioidentical” means the hormones have the same chemical structure as the hormones your body makes (usually estradiol, progesterone, testosterone). “Standard” HRT often uses products that are different molecules (conjugated equine estrogens, synthetic progestins) or FDA-approved forms of estradiol/progesterone. The main practical differences are source/labeling, customization, regulation, and the evidence base — not a proven safety advantage for bioidentical compounded preparations.

What people mean by each term

• Bioidentical hormones
  • Chemically identical to human hormones (e.g., 17β‑estradiol, micronized progesterone).
  • Can be prescribed as FDA‑approved products (oral estradiol, estradiol patches, Prometrium for progesterone) or as custom‑compounded mixtures from compounding pharmacies (“custom BHRT”).
• Standard HRT
  • Historically refers to the classic, FDA‑approved menopausal hormone therapies such as conjugated equine estrogens (Premarin) and synthetic progestins (medroxyprogesterone acetate, Provera). Today many FDA‑approved therapies are bioidentical estradiol and micronized progesterone too — so “standard” overlaps with “bioidentical” depending on the product.

Key practical differences

• Chemical identity: Bioidentical estradiol/progesterone = same molecules as endogenous hormones. Synthetic progestins and conjugated equine estrogens are different molecules.
• Regulation and quality control:
  • FDA‑approved products have manufacturing controls, standardized dosing, and clinical trial data.
  • Compounded bioidentical prescriptions are not FDA‑approved, can vary in dose/consistency, and have less rigorous safety/efficacy data.
• Customization:
  • Compounding allows customized dosages, forms, and combinations (often promoted as an advantage).
  • FDA products come in standard doses and forms with known pharmacology.
• Evidence on safety/efficacy:
  • FDA‑approved estradiol and micronized progesterone have clinical data. Some synthetic progestins (e.g., medroxyprogesterone) were linked in WHI and other studies to different risks (breast cancer signal, cardiovascular effects) depending on formulation and duration.
  • There is no high‑quality evidence that compounded “BHRT” is safer or more effective than comparable FDA‑approved bioidentical products; claims of being more “natural” do not equal safer.
• Route matters: oral vs transdermal vs vaginal affects liver first‑pass, clotting risk, and symptom control. For example, transdermal estradiol patches (Vivelle‑Dot, Climara) may have lower risk of venous thromboembolism than oral estrogen in some studies.

Safety points

• Risk profile depends on your age, time since menopause, dose, formulation, and whether a progestogen is used if you have a uterus.
• Common risks to discuss with your clinician: breast cancer risk, stroke, heart disease, blood clots, and side effects.
• Because compounded products are not FDA‑regulated, they may have variable potency/sterility. If you consider compounding, use a pharmacy accredited by an independent body (PCAB) and discuss why an FDA‑approved product can’t meet your needs.

Examples (brands and why)

• FDA‑approved bioidentical options
  • Estrace (oral estradiol) — standard, well‑studied oral estradiol.
  • Climara or Vivelle‑Dot (transdermal estradiol patches) — transdermal delivery, may lower first‑pass liver effects and clot risk.
  • Estring (vaginal estradiol ring) — local therapy for vaginal symptoms with low systemic exposure.
  • Prometrium (micronized progesterone) — FDA‑approved, bioidentical progesterone option for endometrial protection; differs from synthetic progestins.
• Examples of “standard” (non‑bioidentical/synthetic) products
  • Premarin (conjugated equine estrogens) and Prempro (Premarin + medroxyprogesterone acetate) — historically common HRT formulations; chemically distinct from human estradiol/progesterone.
  • Provera (medroxyprogesterone acetate) — a synthetic progestin often used with estrogen.
• If considering compounding (only when necessary)
  • Use an accredited compounding pharmacy (look for PCAB accreditation or USP compliance). Examples in the U.S. that many clinicians use include Wedgewood Pharmacy and Belmar Pharmacy — but check current accreditation, reviews, and ask your clinician for local recommendations.
• Where to get evidence‑based help
  • Consider consultation with a NAMS (North American Menopause Society)‑aware clinician, a menopause clinic (e.g., Mayo Clinic or Cleveland Clinic menopause programs), or a board‑certified OB/GYN or endocrinologist experienced in menopause care.

How to decide what’s best for you

• Get a medical evaluation: symptoms, medical history, breast cancer/VTE/stroke/heart disease risk, and personal preferences.
• If you have a uterus, you generally need a progestogen along with systemic estrogen to protect the endometrium.
• Prefer FDA‑approved bioidentical options when available. Consider compounding only if a clinically important individualized dosage or form cannot be obtained as an approved product and use an accredited compounding pharmacy.
• Follow-up and monitoring: start with the lowest effective dose, reassess symptoms and side effects, and review risks periodically.

Bottom line “Bioidentical” describes molecular identity; “standard HRT” describes traditional formulations and includes both bioidentical and non‑bioidentical products. FDA‑approved bioidentical products (estradiol, micronized progesterone) have known quality and evidence. Compounded BHRT is customizable but less regulated and not proven safer. Discuss options with a clinician who can tailor the choice to your health profile and risk factors. If you want, tell me your symptoms, age, and any medical history and I can summarize options and what to discuss with your clinician.